Grant, identification of immune signatures linked to military-related toxicant exposure as biomarkers for GWI diagnosis and therapeutic response

The Defense Health Agency awarded The Roskamp Institute, Inc. $770,000 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to identify immune signatures linked to military-related toxicant exposure as biomarkers for Gulf War Illness diagnosis and therapeutic response.

Performance runs through August 31, 2029, at the recipient's facility in Sarasota, Florida. The project represents one of multiple concurrent Defense Health Agency grants to the institute targeting traumatic brain injury and Gulf War Illness pathophysiology; the institute's broader Defense Health Agency portfolio under CFDA 12.420 totals approximately $7.9 million across awards investigating blood-brain-barrier-penetrable peroxisome proliferator-activated receptor agonists for repetitive mild traumatic brain injury, ultraselective DYRK1A inhibitors for traumatic brain injury, microglial inflammasome activation, PTEN signaling in chronic TBI sequelae, and amnion-derived cell therapies for Gulf War Illness and traumatic brain injury.

The Roskamp Institute is a tax-exempt nonprofit biotechnology research organization specializing in preclinical neuroscience research. The institute maintains a diversified federal grant portfolio spanning 78 awards, with primary customer concentration at the Department of Veterans Affairs Veterans Integrated Service Network 8, Defense Health Agency, National Institute on Aging, and Army Medical Command.